Reporte zur Charge UI169AA

Symptomtext

tachycardia; increased respirations by the end of her shift; a rash on her back and chest, rash spread to her face and scalp and went down below; Initial information regarding an unsolicited valid non serious case was received from physician and consumer/non-health care professional via Medical Information (Reference number- 00766524) and transmitted to Sanofi on 13-Sep-2021. This case involves a 45-year-old female patient who experienced tachycardia, increased respirations by the end of shift (respiration rate increased), and a rash on her back and chest, rash spread to her face and scalp and went down below (rash) after receiving vaccine INFLUENZA QUADRIVAL A-B VACCINE [FLUZONE QUADRIVALENT]. Past medical treatment, vaccination and family history were not provided. The patient's past medical treatment, vaccination and family history were not provided. Past medical history was reported, the patient had ongoing drug allergy, cosmetic allergy and spice allergy. Concomitant medications included DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) LORATADINE (CLARITIN [LORATADINE]) PARACETAMOL (TYLENOL) allergy prophylaxis. On 24-Sep-2014, the patient received a total first dose of suspect INFLUENZA QUADRIVAL A-B VACCINE [frequency: once, strength: standard, lot UI169AA, expiry date not reported] via an intramuscular route in right deltoid for prophylactic vaccination. In 2014, the patient developed a non-serious rash on her back and chest, rash spread to her face and scalp and went down below (rash) (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE. On an unknown date the patient developed a non-serious tachycardia, increased respirations by the end of her shift (respiration rate increased) (unknown latency) following the administration of INFLUENZA QUADRIVAL A-B VACCINE. No other vaccines. The reporter reported "Caller states that she received the vaccine at the hospital that she worked for and they are now trying to mandate a coronavirus disease (COVID-19) vaccine for all employees. caller is trying to determine if the FLUQUAD ID PF vaccine contained any of the same preservatives as the COVID-19 vaccine so that she may be exempt from receiving it. caller states that she prophylactically took Benadryl, Claritin, and Tylenol prior to the FLUQUAD ID PF vaccine because of her allergy history." Other laboratory details were not reported. It was not reported if the patient received a corrective treatment for the events. On unknown date, patient was recovered for all events.